Expression data from skin biopsies in pateints with systemic sclerosis treated with anti-TGF-beta, fresolimumab

ABSTRACT: Systemic sclerosis is associated with skin fibrosis thought mediated by TGFb. This open label clinical trial examines the effect of TGFb inhibition on skin gene expression. Patients 1-9 received two doses 1 mg/kg dose of fresolimumab at baseline and 3 weeks; patients 10-19 received a single 5 mg/kg dose Patients with diffuse cutaneous systemic sclerosis within 2 years of first raynauds had skin biopsies before treatment and the 3-4 weeks, 7 weeks and 24 weeks after treatment with fresolimumab

ORGANISM(S): Homo sapiens

SUBMITTER: Robert Lafyatis 

PROVIDER: E-GEOD-55036 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress